SEC For					тс	<u> </u>				יה ב	VCUA								
	FORM	UNITED STATES SECURITIES AND EXCHANGE COMI Washington, D.C. 20549												OMB APPROVAL			VAL		
Check this box if no longer subject to SECTION 16. Form 4 or Form 5 obligations may continue. See					NT	OF	CHA	١GI	ES IN	BEN	NEFIC	VNERS	Estin			verage burde	3235-0287 en 0.5		
Instruction 1(b). Filed pu						ursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940													
						2. Issuer Name and Ticker or Trading Symbol <u>Milestone Pharmaceuticals Inc.</u> [MIST]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) (First) (Middle) 40 10TH AVENUE, FLOOR 7					3. Date of Earliest Transaction (Month/Day/Year) 05/21/2021									Officer (give title Other (specify below) below)					
				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) NEW YORK NY 10014														Form filed by One Reporting Person X Form filed by More than One Reporting Person					
(City)	(S	itate)	(Zip)																
1 Title of	C		ble I - Noi						cquired	, Dis		of, or Be		1		6.00		7 Nature of	
1. Title of Security (Instr. 3)				2. Transa Date (Month/D			2A. Deemed Execution Date if any (Month/Day/Yea		e, Trans Code	action (Instr.			str. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported	s ally ollowing	Form: D	vnership I: Direct I Indirect Istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) ((D)	Price	Transaction(s) (Instr. 3 and 4)				(
			Table II -									, or Ben ible sec		Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, 4.	4. Transaction Code (Instr.		5. Number of		6. Date E Expiratio (Month/D	xercis	able and	7. Title ar of Securi Underlyir	nd Amount ties ng e Security	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Beneficia Owned Followin Reported	e es ally g	y Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
				Co	ode	v	(A)			Date E Exercisable D		Title	Amount or Number of Shares]	Transaction(s (Instr. 4)				
Pre- Funded Warrant ⁽²⁾	\$0.01	05/21/2021		1	P		910,746		05/21/20)21	(3)	Common Stock	910,746	\$5.48	8,518,	257	I	By RTW ⁽¹⁾	
		Reporting Person [*] IENTS, LP	ż																
(Last) (First) (Middle) 40 10TH AVENUE, FLOOR 7																			
(Street) NEW YORK		NY 10014		4															
(City) (State)		(State)	(Zip)																
	nd Address of	Reporting Person [*] RICK	¢																
(Last) (First) C/O RTW INVESTMENTS, LP 40 10TH AVENUE, FLOOR 7			(Middle)																
(Street) NEW YORK		NY	10014																
(City)		(State)	(Zip)																

Explanation of Responses:

1. The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "Funds"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the Funds, except to the extent of its or his pecuniary interest therein.

2. Each pre-funded warrant represents the right to acquire one share of common stock for an exercise price of \$0.01 per share. The ability of the holder to exercise the pre-funded warrant is subject to a beneficial ownership limitation initially set at 9.99% of the Company's issued and outstanding common stock. This beneficial ownership limitation may be increased or decreased at the election of the warrant holder, provided that any increase shall not be effective until the 61st day after notice of adjustment is provided to the Company.

3. The warrants do not have an expiration date.

RTW Investments, LP; By: /s/
attorney-in-fact for RTW05/24/2021Investments, LP/s/ Alice Lee, attorney-in-fact05/24/2021

for Roderick Wong

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.